Ischemic Stroke in Patients with Cancer: A Retrospective Cross-Sectional Study

1Rickles FR, Edwards RL. Activation of blood coagulation in cancer: Trousseau’s syndrome revisited. Blood. 1983;62:1431. Rickles FR Edwards RL Activation of blood coagulation in cancer: Trousseau’s syndrome revisited Blood 1983621431Search in Google Scholar

2Graus F, Rogers LR, Posner JB. Cerebrovascular complications in patients with cancer. Medicine. 1985; 64:16-35. Graus F Rogers LR Posner JB Cerebrovascular complications in patients with cancer Medicine 1985 6416 3510.1097/00005792-198501000-000023965856Search in Google Scholar

3Cestari DM, Weine DM, Panageas KS, Segal AZ, DeAngelis LM. Stroke in patients with cancer: incidence and aetiology. Neurology. 2004;65: 2025-30. Cestari DM Weine DM Panageas KS Segal AZ DeAngelis LM Stroke in patients with cancer: incidence and aetiology Neurology 200465 2025 3010.1212/01.WNL.0000129912.56486.2B15184609Search in Google Scholar

4Navi BB, Reiner AS, Kamel H, et al. association between incident cancer and subsequent stroke. Ann Neurol.2015;77:291-300. Navi BB Reiner AS Kamel H et al association between incident cancer and subsequent stroke Ann Neurol 2015 77291 30010.1002/ana.24325431570325472885Search in Google Scholar

5Navi BB, Iadecola C. Ischemic stroke in cancer patients: a review of an underappreciated pathology. Ann Neurol. 2018;83: 873-83. Navi BB Iadecola C Ischemic stroke in cancer patients: a review of an underappreciated pathology Ann Neurol 201883 873 8310.1002/ana.25227602122529633334Search in Google Scholar

6Schwarzbach CJ, Schaefer A, Ebert A, et al. stroke and cancerthe importance of cancer-associated hypercoagulation as a possible stroke aetiology. Stroke.2012;43:3029-34. Schwarzbach CJ Schaefer A Ebert A et al stroke and cancerthe importance of cancer-associated hypercoagulation as a possible stroke aetiology Stroke 2012 433029 3410.1161/STROKEAHA.112.65862522996958Search in Google Scholar

7Henley SJ, Singh SD, King J, Wilson RJ, O’Neil ME, Ryerson AB. Invasive cancer incidence and survival -United States, 2012. Morb Mortal Wkly Rep. 2015; 64:1353-58. Henley SJ Singh SD King J Wilson RJ O’Neil ME Ryerson AB Invasive cancer incidence and survival -United States, 2012 Morb Mortal Wkly Rep 2015 641353 5810.15585/mmwr.mm6449a126678069Search in Google Scholar

8Kneihsl M, Enzinger C, Wunsch G, et al. Poor short-term outcome in patients with ischaemic stroke and active cancer. J Neurol. 2016; 263:150-56. Kneihsl M Enzinger C Wunsch G et al Poor short-term outcome in patients with ischaemic stroke and active cancer J Neurol 2016 263150 5610.1007/s00415-015-7954-626530513Search in Google Scholar

9Taccone FS, Jeangette SM, Blecic SA. First-ever stroke as initial presentation of systemic cancer. J Stroke Cerebrovasc Dis. 2008;17: 169-74. Taccone FS Jeangette SM Blecic SA First-ever stroke as initial presentation of systemic cancer J Stroke Cerebrovasc Dis 200817 169 7410.1016/j.jstrokecerebrovasdis.2008.01.00718589335Search in Google Scholar

10Bhattacharjee M, Vairale J, Gawali K, Dalal PM. Factors affecting burden on caregivers of stroke survivors: Population-based study in Mumbai (India). Ann Indian Acad Neurol. 2012;15:113–119. Bhattacharjee M Vairale J Gawali K Dalal PM Factors affecting burden on caregivers of stroke survivors: Population-based study in Mumbai (India) Ann Indian Acad Neurol 201215113 11910.4103/0972-2327.94994334558722566724Search in Google Scholar

11Stefan O, Vera N, Otto B, Heinz L,Wolfgang G. Stroke in cancer patients: a risk factor analysis. J Neurooncol.2009;94:221-26. Stefan O Vera N Otto B Heinz LWolfgang G Stroke in cancer patients: a risk factor analysis J Neurooncol 2009 94221 2610.1007/s11060-009-9818-319280119Search in Google Scholar

12Balasa A, Chinezu R, Teleanu DM, Pascanu MI, Chinezu L, Borda A. Ectopic intracavernous corticotroph microadenoma: case report of an extremely rare pathology. Rom J Morphol Embryol. 2017;58:1447-1451. Balasa A Chinezu R Teleanu DM Pascanu MI Chinezu L Borda A Ectopic intracavernous corticotroph microadenoma: case report of an extremely rare pathology Rom J Morphol Embryol 2017581447 1451Search in Google Scholar

13Edwardson DW, Boudreau J, Mapletoft J, Lanner C, Kovala AT, Parissenti AM. Inflammatory cytokine production in tumour cells upon chemotherapy drug exposure or upon selection for drug resistance. PLoS One. 2017;12(9):e0183662. Edwardson DW Boudreau J Mapletoft J Lanner C Kovala AT Parissenti AM Inflammatory cytokine production in tumour cells upon chemotherapy drug exposure or upon selection for drug resistance PLoS One 2017129e018366210.1371/journal.pone.0183662560039528915246Search in Google Scholar

14Bamford J, Sandercock P, Dennis M, et al. A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-1986 1. Methodology, demography and incident cases of first-ever stroke. J Neurol Neurosurg Psychiatry 1988;51:1373-80. Bamford J Sandercock P Dennis M et al A prospective study of acute cerebrovascular disease in the community: the Oxfordshire Community Stroke Project 1981-1986 1 Methodology, demography and incident cases of first-ever stroke. J Neurol Neurosurg Psychiatry 1988511373 8010.1136/jnnp.51.11.137310328053266234Search in Google Scholar

15Adams HP Jr, Bendixen BH, Kappelle LJ, et al. classification of subtype of acute ischemic stroke. Definitions for use in multicenter clinical trials. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke.1993;24:35-41. Adams HP Jr Bendixen BH Kappelle LJ et al classification of subtype of acute ischemic stroke Definitions for use in multicenter clinical trials. TOAST. Trial of Org 10172 in Acute Stroke Treatment. Stroke 1993 2435 41Search in Google Scholar

16Jang H-S, Choi J, Shin J, et al. The long-term effect of cancer on incident stroke: a nationwide population-based cohort study in Korea. Front Neurol.2019;10:52. Jang H-S Choi J Shin J et al The long-term effect of cancer on incident stroke: a nationwide population-based cohort study in Korea Front Neurol 2019 105210.3389/fneur.2019.00052637061730804874Search in Google Scholar

17Lee MJ, Chung JW, Ahn MJ, et al. Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study. J Stroke. 2017;19(1):77–87. Lee MJ Chung JW Ahn MJ et al Hypercoagulability and Mortality of Patients with Stroke and Active Cancer: The OASIS-CANCER Study J Stroke 201719177 8710.5853/jos.2016.00570530794128030894Search in Google Scholar

18Khorana AA, Francis CW, Culakova E, Fisher RI, Kuderer NM, Lyman GH. Thromboembolism in hospitalized neutropenic cancer patients. J Clin Oncol. 2006;24(3):484-90. Khorana AA Francis CW Culakova E Fisher RI Kuderer NM Lyman GH Thromboembolism in hospitalized neutropenic cancer patients J Clin Oncol 2006243484 9010.1200/JCO.2005.03.887716421425Search in Google Scholar

19Selvik HA, Thomassen L, Bjerkreim AT, Naess H. Cancer-associated stroke: the Bergen NORSTROKE Study. Cerebrovasc Dis Extra.2015;5:107-113. Selvik HA Thomassen L Bjerkreim AT Naess H Cancer-associated stroke: the Bergen NORSTROKE Study Cerebrovasc Dis Extra 2015 5107 11310.1159/000440730466234026648966Search in Google Scholar

20Dammacco F, Vacca A, Procaccio P, Ria R, Marech I, Racanelli V. Cancer-related coagulopathy: a review of literature and experience of a single centre of internal medicine. Clin Exp Med 2013;13:85-97. Dammacco F Vacca A Procaccio P Ria R Marech I Racanelli V Cancer-related coagulopathy: a review of literature and experience of a single centre of internal medicine Clin Exp Med 20131385 9710.1007/s10238-013-0230-023456539Search in Google Scholar

21Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia.2002;4:465-73. Caine GJ Stonelake PS Lip GY Kehoe ST The hypercoagulable state of malignancy: pathogenesis and current debate Neoplasia 2002 4465 7310.1038/sj.neo.7900263155033912407439Search in Google Scholar

22Zuo PY, Chen XL, Liu YW, Xiao CL, Liu CY. Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis. PloS One, 2014; 9: e102484. Zuo PY Chen XL Liu YW Xiao CL Liu CY Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis PloS One 2014 9 e10248410.1371/journal.pone.0102484409917825025282Search in Google Scholar

23Lysov Z, Dwivedi DJ, Gould TJ, Liaw PC. Procoagulant effects of lung cancer chemotherapy: impact on microparticles and cell-free DNA. Blood Coagul Fibrinolysis. 2017; 28:72-82. Lysov Z Dwivedi DJ Gould TJ Liaw PC Procoagulant effects of lung cancer chemotherapy: impact on microparticles and cell-free DNA Blood Coagul Fibrinolysis 2017 2872 8210.1097/MBC.000000000000054626919453Search in Google Scholar

24Hung SK, Lee MS, Chiou WY, et al. High incidence of ischemic stroke occurrence in irradiated lung cancer patients: a population-based surgical cohort study. PloS One. 2014; 9:e94377. Hung SK Lee MS Chiou WY et al High incidence of ischemic stroke occurrence in irradiated lung cancer patients: a population-based surgical cohort study PloS One 2014 9e9437710.1371/journal.pone.0094377397803924709837Search in Google Scholar

25Ay C, Pabinger I, Cohen AT. Cancer-associated venous thromboembolism: Burden, mechanisms, and management. Thromb Haemost. 2017;117(2):219-230. Ay C Pabinger I Cohen AT Cancer-associated venous thromboembolism: Burden, mechanisms, and management Thromb Haemost 20171172219 23010.1160/TH16-08-061527882374Search in Google Scholar

26Falanga A, Alessio MG, Donati MB, Barbui T. A new procoagulant in acute leukemia. Blood 1988; 71: 870–875. Falanga A Alessio MG Donati MB Barbui T A new procoagulant in acute leukemia Blood 1988 71 870 87510.1182/blood.V71.4.870.870Search in Google Scholar

27Kazmierczak M, Lewandowski K, Wojtukiewicz MZ, et al. Cancer procoagulant in patients with adenocarcinomas. Blood Coagul Fibrinolysis 2005; 16: 543–547. Kazmierczak M Lewandowski K Wojtukiewicz MZ et al Cancer procoagulant in patients with adenocarcinomas Blood Coagul Fibrinolysis 2005 16 543 54710.1097/01.mbc.0000188413.32859.b216269926Search in Google Scholar

28Ueno T, Toi M, Koike M, Nakamura S, Tominaga T. Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration. Br J Cancer. 2000; 83: 164–170. Ueno T Toi M Koike M Nakamura S Tominaga T Tissue factor expression in breast cancer tissues: its correlation with prognosis and plasma concentration Br J Cancer 2000 83 164 17010.1054/bjoc.2000.1272236347510901365Search in Google Scholar

29Uno K, Homma S, Satohet T, et al. Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer. Br J Cancer. 2007; 96: 290–295. Uno K Homma S Satohet T et al Tissue factor expression as a possible determinant of thromboembolism in ovarian cancer Br J Cancer 2007 96 290 29510.1038/sj.bjc.6603552235999617211468Search in Google Scholar

30Sinauridze EI, Kireev DA, Popenko NY, et al. Platelet microparticle membranes have 50– to 100-fold higher specific procoagulant activity than activated platelets. Thromb Haemost. 2007; 97: 425–434. Sinauridze EI Kireev DA Popenko NY et al Platelet microparticle membranes have 50– to 100-fold higher specific procoagulant activity than activated platelets Thromb Haemost 2007 97 425 43410.1160/TH06-06-0313Search in Google Scholar

31Seruga B, Zhang H, Bernstein LJ, Tannock IF. Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer. 2008; 8: 887–899. Seruga B Zhang H Bernstein LJ Tannock IF Cytokines and their relationship to the symptoms and outcome of cancer Nat Rev Cancer 2008 8 887 89910.1038/nrc250718846100Search in Google Scholar

32Kirchhofer D, Tschopp TB, Hadváry P, Baumgartner HR. Endothelial cells stimulated with tumor necrosis factoralpha express varying amounts of tissue factor resulting in homogenous fibrin deposition in a native blood flow system. Effects of thrombin inhibitors. J Clin Invest. 1994; 93: 2073– 2083. Kirchhofer D Tschopp TB Hadváry P Baumgartner HR Endothelial cells stimulated with tumor necrosis factoralpha express varying amounts of tissue factor resulting in homogenous fibrin deposition in a native blood flow system Effects of thrombin inhibitors. J Clin Invest 1994 93 2073–208310.1172/JCI1172022943278182139Search in Google Scholar

33Szotowski B, Antoniak S, Poller W, Schultheiss HP, Rauch U. Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines. Circ Res. 2005; 96: 1233–1239. Szotowski B Antoniak S Poller W Schultheiss HP Rauch U Procoagulant soluble tissue factor is released from endothelial cells in response to inflammatory cytokines Circ Res 2005 96 1233 123910.1161/01.RES.0000171805.24799.fa15920023Search in Google Scholar

34Bernardo A, Ball C, Nolasco L, Moake JF, Dong JF. Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers underflow. Blood. 2004; 104: 100–106. Bernardo A Ball C Nolasco L Moake JF Dong JF Effects of inflammatory cytokines on the release and cleavage of the endothelial cell-derived ultralarge von Willebrand factor multimers underflow Blood 2004 104 100 10610.1182/blood-2004-01-010715026315Search in Google Scholar

35Fuchs TA, Brill A, Wagner DD. Neutrophil extracellular trap (NET) impact on deep vein thrombosis. Arterioscler Thromb Vasc Biol 2012; 32: 1777–1783. Fuchs TA Brill A Wagner DD Neutrophil extracellular trap (NET) impact on deep vein thrombosis Arterioscler Thromb Vasc Biol 2012 32 1777 178310.1161/ATVBAHA.111.242859349559522652600Search in Google Scholar

36Binder BR, Christ G, Gruber F, et al. Plasminogen activator inhibitor 1: physiological and pathophysiological roles. News Physiol Sci. 2002; 17: 56–61. Binder BR Christ G Gruber F et al Plasminogen activator inhibitor 1: physiological and pathophysiological roles News Physiol Sci 2002 17 56 6110.1152/nips.01369.200111909993Search in Google Scholar

37Grisold W, Oberndorfer S, Struhal W. Stroke and cancer: a review. Acta Neurol Scand.2009;119:1-16. Grisold W Oberndorfer S Struhal W Stroke and cancer: a review Acta Neurol Scand 2009 1191 1610.1111/j.1600-0404.2008.01059.x18616624Search in Google Scholar

38Zhang YY, Cordato D, Shen Q, Sheng AZ, Hung WT, Chan DK. Risk factor, pattern, etiology and outcome in ischemic stroke patients with cancer: a nested case-control study. Cerebrovasc Dis.2007;23:181-87. Zhang YY Cordato D Shen Q Sheng AZ Hung WT Chan DK Risk factor, pattern, etiology and outcome in ischemic stroke patients with cancer: a nested case-control study Cerebrovasc Dis 2007 23181 8710.1159/00009763917143001Search in Google Scholar

39Stefan O, Vera N, Otto B, Heinz L, Wolfgang G. Stroke in cancer patients: a risk factor analysis. J Neurooncol.2009;94:221-26. Stefan O Vera N Otto B Heinz L Wolfgang G Stroke in cancer patients: a risk factor analysis J Neurooncol 2009 94221 2610.1007/s11060-009-9818-319280119Search in Google Scholar

40Katsiari CG, Bogdanos DP, Sakkas LI. Inflammation and cardiovascular disease. World J Transl Med. 2019; 8(1): 1-8. Katsiari CG Bogdanos DP Sakkas LI Inflammation and cardiovascular disease World J Transl Med 2019 81 1 810.5528/wjtm.v8.i1.1Search in Google Scholar

41Kim K, Lee J-H. Risk factors and biomarkers of ischemic stroke in cancer patients. J Stroke.2014;16:91-6. Kim K Lee J-H Risk factors and biomarkers of ischemic stroke in cancer patients J Stroke 2014 1691 610.5853/jos.2014.16.2.91406027324949315Search in Google Scholar

42Nguyen T, DeAngelis LM. Stroke in cancer patients. Curr Neurol Neurosci Rep.2006;6:187-92. Nguyen T DeAngelis LM Stroke in cancer patients Curr Neurol Neurosci Rep 2006 6187 9210.1007/s11910-006-0004-016635426Search in Google Scholar

43Kim SG, Hong JM, Kim HY, et al. Ischemic stroke cancer in patients with and without conventional mechanism. Stroke. 2010;41:798-801. Kim SG Hong JM Kim HY et al Ischemic stroke cancer in patients with and without conventional mechanism Stroke 201041798 80110.1161/STROKEAHA.109.57135620150545Search in Google Scholar

44Alvarez-Perez FJ, Castelo-Branco M, Alvarez-Sabin J. Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischemic stroke. J Neurol Neurosurg Psychiatry.2011;82:986-92. Alvarez-Perez FJ Castelo-Branco M Alvarez-Sabin J Usefulness of measurement of fibrinogen, D-dimer, D-dimer/fibrinogen ratio, C reactive protein and erythrocyte sedimentation rate to assess the pathophysiology and mechanism of ischemic stroke J Neurol Neurosurg Psychiatry 2011 82986 9210.1136/jnnp.2010.23087021296900Search in Google Scholar

45Aarnio K, Joensuu H, Haapaniemi E, et al. Cancer in young adults with ischemic stroke. Stroke.2015;46:1601-6. Aarnio K Joensuu H Haapaniemi E et al Cancer in young adults with ischemic stroke Stroke 2015 461601 610.1161/STROKEAHA.115.00869425922510Search in Google Scholar

46Chen PC, Muo CH, Lee YT, Yu YH, Sung FC. Lung cancer and incidence of stroke: a population-based cohort study. Stroke.2011;42:3034-39. Chen PC Muo CH Lee YT Yu YH Sung FC Lung cancer and incidence of stroke: a population-based cohort study Stroke 2011 423034 3910.1161/STROKEAHA.111.61553421903961Search in Google Scholar

47Bick RL. Cancer-associated thrombosis. N Engl J Med.2003;349:109-11. Bick RL Cancer-associated thrombosis N Engl J Med 2003 349109 1110.1056/NEJMp03008612853582Search in Google Scholar

48Cutting S, Wettengel M, Conners JJ, Ouyang B, Busl K. Three-months outcomes are poor in stroke patients with cancer despite acute stroke treatment. J Stroke Cerebrovasc Dis. 2017;26:809-15. Cutting S Wettengel M Conners JJ Ouyang B Busl K Three-months outcomes are poor in stroke patients with cancer despite acute stroke treatment J Stroke Cerebrovasc Dis 201726809 1510.1016/j.jstrokecerebrovasdis.2016.10.02127890440Search in Google Scholar